The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer
Status
Conditions
Treatments
Details and patient eligibility
About
Previous research has shown that microRNAs in the blood can serve as biomarkers for early pancreatic cancer, with potential applications including detection, differential diagnosis, and prognosis prediction of pancreatic cancer. The current primary method for detecting microRNAs is RT-qPCR, but this process requires repeated temperature cycling, which demands high precision from the equipment. As an alternative, isothermal nucleic acid amplification technology does not require expensive temperature control instruments. Our research team has developed various isothermal nucleic acid amplification strategies for microRNA sensing platforms, applied to biological sample detection. This study combines the circular strand displacement amplification strategy with DNA nanomachines to develop a fluorescence sensing platform that performs dual signal amplification at a constant temperature. It is designed to detect pancreatic cancer-related microRNAs, exploring its role and potential applications in the diagnosis of pancreatic cancer patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Pancreatic ductal adenocarcinoma
- Proven by pathology
- Patients who have not received anti-cancer therapies
Exclusion criteria
- Less than 20 years old
- Unable to provide inform and consent
- Patients who have active malignancy other than pancreatic adenocarcinoma
- Patients who have had pancreatic cancer whose anti-cancer therapies are completed or undergoing
- Life expectancy less than 3 months
Trial design
30 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Weng Fai Wong, Master of Science
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal